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Infrapopliteal angioplasty for critical limb
ischemia: Relation of TransAtlantic InterSociety
Consensus class to outcome in 176 limbs
Kristina A. Giles, MD, Frank B. Pomposelli, MD, Allen D. Hamdan, MD, Seth B. Blattman, MD,
Haig Panossian, BS, and Marc L. Schermerhorn, MD, Boston, Mass
Objective: Recent data suggest that percutaneous transluminal angioplasty (PTA) may be appropriate primary therapy for
critical limb ischemia (CLI). However, little data are available regarding infrapopliteal angioplasty outcomes based on
TransAtlantic InterSociety Consensus (TASC) classification. We report our experience with infrapopliteal angioplasty
stratified by TASC lesion classification.
Methods: From February 2004 toMarch 2007, 176 consecutive limbs (163 patients) underwent infrapopliteal angioplasty
for CLI. Stents were placed for lesions refractory to PTA or flow-limiting dissections. Patients were stratified by TASC
classification and suitability for bypass grafting. Primary outcome was freedom from restenosis, reintervention, or
amputation. Primary patency, freedom from secondary restenosis, limb salvage, reintervention by repeat angioplasty or
bypass, and survival were determined.
Results: Median age was 73 years (range, 39-94 years). Technical success was 93%. Average follow-up was 10 months
(range, 1-41 months). At 1 and 2 years, freedom from restenosis, reintervention, or amputation was 39% and 35%,
conventional primary patency was 53% and 51%, and freedom from secondary restenosis and reintervention were 63% and
61%, respectively. Limb salvage was 84% at 1, 2, and 3 years. Within 2 years, 15% underwent bypass and 18% underwent
repeat infrapopliteal PTA. Postoperative complications occurred in 9% and intraprocedural complications in 10%. The
30-day mortality was 5% (9 of 181). Overall survival was 81%, 65%, and 54% at 1, 2, and 3 years. TASC D classification
predicted diminished technical success (75% D vs 100% A, B, and C; P < .001), primary restenosis, reintervention, or
amputation (hazard ratio [HR], 3.4; 95% confidence interval [CI], 2.1-5.5, P < .001), primary patency (HR, 2.2; 95%
CI, 1.3-3.9, P < .004), secondary restenosis (HR, 3.2; 95% CI, 1.6-6.4, P  .001), and limb salvage (HR, 2.6; 95% CI,
1.1-6.3, P < .05). Unsuitability for surgical bypass also predicted restenosis, reintervention, or amputation, secondary
restenosis, need for repeated angioplasty, and inferior primary patency and limb salvage rates.
Conclusion: Infrapopliteal angioplasty is a reasonable primary treatment for CLI patients with TASC A, B, or C lesions.
Restenosis, reintervention, or amputation was higher in patients who were unsuitable candidates for bypass; however, an
attempt at PTA may be indicated as an alternative to primary amputation. Although restenosis, reintervention, or
amputation is high after tibial angioplasty for CLI, excellent limb salvage rates may be obtained with careful follow-up
and reinterventions when necessary, including bypass in 15%. (J Vasc Surg 2008;48:128-36.)Good technical and clinical results have been obtained
with pedal bypass for the treatment of tibial occlusive
disease causing limb ischemia.1 A combination of excellent
durability and low mortality make this procedure an attrac-
tive option for patients with a threatened extremity. How-
ever, significant morbidity can be associated with distal
bypass surgery. A mortality rate approximating 2% is typi-
cally cited, but some studies have found rates as high as 5%
to 12%.1-7Moreover, not all patients are suitable candidates
for distal bypass surgery. Patients may lack conduit or
target, be nonambulatory, have a limited life expectancy,
have an extensive soft tissue infection overlying a bypass
target, or infrequently have comorbidities that make them
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128an unacceptable risk. In these patients, percutaneous trans-
luminal angioplasty (PTA) may constitute a feasible revas-
cularization method rather than primary amputation.
Recently, the Bypass Versus Angioplasty in Severe Isch-
emia of the Leg (BASIL) study suggested that if the anatomy
is conducive for angioplasty, primary PTAmight be an appro-
priate first therapy even if the patient is a good candidate for
bypass. Ideal anatomy was not well defined in BASIL, how-
ever, and outcomes were not stratified by the distal extent of
disease (superficial femoral/popliteal/tibial).7
Outcomes of tibial PTA are difficult to predict from the
existing literature owing to a lack of details regarding
indications for intervention and lesion characteristics.6-17
The TransAtlantic InterSociety Consensus (TASC) criteria
represents a standardized definition for lesion characteris-
tics (Table I).8,9 Our objective was to review our results of
infrapopliteal angioplasty stratifying patients by anatomic
characteristics according to the TASC classification.
METHODS
We performed a retrospective study analyzing periop-
erative and follow-up outcomes of infrapopliteal angio-
plasty for patients with critical limb ischemia. The study
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ical Center (BIDMC) Institutional Review Board.
Subjects and setting. All patients who underwent an
endovascular procedure performed by a member of the
Division of Vascular and Endovascular Surgery at the
BIDMC consecutively from February 2004 toMarch 2007
were recorded in a computerized vascular registry. Demo-
graphics, procedural details, and in-hospital outcomes are
prospectively recorded in this registry. From this database,
we retrospectively reviewed all patients who underwent an
attempt at a percutaneous, infrapopliteal angioplasty pro-
cedure on a native vessel.
Interventions were performed for critical limb ischemia
(CLI), defined as tissue loss, rest pain, or a stenosis in the
outflow vessel of a tibial bypass combined with low graft
flow velocities that threatened the graft viability. Not in-
cluded in this review are five interventions that were
performed during this time period for disabling claudi-
cation in patients who also had concurrent femoropop-
liteal disease. Preoperative segmental pressures and
Doppler waveforms were obtained in all elective cases. In
our patients with diabetes, we routinely obtain forefoot
pulse volume recordings because of the well-known un-
reliability of ankle-brachial index (ABI) measurements in
these patients. Palpable distal pulses were absent in all
patients, and all patients with preoperative vascular stud-
ies had dampened forefoot pulse volume recordings.
Most cases were performed in a dedicated angiography
suite, initially in a cardiac catheterization laboratory and
eventually in an operating room endovascular suite. A few
were performed in a standard operating roomwith amobile
C-arm. Most procedures were performed under conscious
sedation; however, general anesthesia was occasionally used
for patients unable to adequately lie still.
All patients were anticoagulated with heparin during
the procedure to an activating clotting time of 250 to 300
seconds. After the procedure, patients were given a loading
dose of clopidogrel and maintained on a 75-mg daily dose
for at least 30 days, along with aspirin and statin therapy
indefinitely.
Cases were performed using 5F or 6F sheaths preferen-
tially through retrograde contralateral and occasionally
through antegrade ipsilateral access. No brachial or other
Table I. TransAtlantic Inter-Society Consensus
classification for infrapopliteal lesions9
Classification Lesion characteristics
TASC A Single stenosis 1 cm long
TASC B Multiple focal stenoses 1 cm long or 1 or
2 stenoses 1 cm involving the
trifurcation
TASC C Stenoses 1 to 4 cm long, occlusion 1 to 2
cm long, or extensive stenosis involving
the trifurcation
TASC D Occlusion 2 cm long or diffusely diseased
TASC, TransAtlantic Inter-Society Consensus.upper extremity access was used. Preference was given tousing 0.014- or 0.018-inch guidewire and catheter sys-
tems. Angioplasty was performed with noncompliant low-
profile balloons. Repeated 2- to 3-minute inflations or
cutting balloon angioplasty were performed if significant
residual stenosis or flow-limiting dissection was present
after a first angioplasty attempt. Subintimal angioplasty was
performed for complete occlusions that could not be
crossed within the lumen. Stents were placed only for
flow-limiting dissections or residual stenosis 30% after
primary angioplasty. The type of stent used depended on
operator preference and availability. Our current preference
is a low-profile self-expanding nitinol stent.
Measurements. We recorded patient demographics,
TASC classification, indication, and bypass candidacy sta-
tus. The primary outcome variable was freedom from reste-
nosis, reintervention, or amputation. Secondary outcomes
were technical success, procedural and postoperative com-
plications, conventional primary patency, secondary reste-
nosis, tissue healing, limb salvage, reintervention, and pa-
tient survival.
TASC classification was assessed for the individual ves-
sel that underwent intervention. If more than one vessel
had a successful intervention, the limb was assigned the
worst of the TASC classes for lesions in series (eg, tibio-
peroneal trunk and posterior tibial) and the lesser class for
lesions in parallel (eg, anterior tibial and posterior tibial).
The indication for the procedure was classified as tissue
loss (gangrene or nonhealing ulcer) or rest pain. A few
patients were treated for the presence of tibial outflow
stenosis in the native tibial artery distal to an existing vein
graft with low graft velocities. All bypass grafts had initially
been placed for either tissue loss or rest pain.
Patients were deemed unsuitable candidates for a by-
pass procedure if they lacked a bypass target or an adequate
vein conduit. A small number of patients had underlying
conditions precluding surgery, including severe dementia,
significant medical comorbidities, nonambulatory status,
or open wounds overlying the only potential bypass target.
Outcome variables. Technical success was defined as
a residual stenosis of 30% as assessed on single-view
completion angiography. Adjunctive procedures included
stent placement, mechanical atherectomy, mechanical
thrombectomy, thrombolysis, or intra-arterial nitroglyc-
erin infusion to treat flow-limiting spasm. Concomitant
procedures included superficial femoral artery, popliteal, or
vein graft angioplasty or stent placement, or both.
Patients were seen for follow-up typically at 2 weeks,
then every 3 months for 1 year, and every 6 months
thereafter, or more frequently if stenoses were detected or
to monitor wound healing. Restenosis and patency were
assessed with duplex ultrasound (DUS) analysis of the
treated vessel, Doppler waveforms, segmental pressures,
pulse volume recordings, and when indicated, angiogra-
phy. All noninvasive vascular studies were performed in one
of two vascular laboratories by a dedicated vascular techni-
cian and interpreted by a staff vascular surgeon.
The primary outcome was freedom from tibial resteno-
sis, reintervention, or major amputation. Restenosis was
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by peak systolic velocity ratio increase of3.0 on the DUS
examination. In our vascular laboratory, this value repre-
sents 60% to 80% vessel stenosis and is consistent with
reporting standards for prior endovascular series.10
Measurement of primary patency followed Society for
Vascular Surgery (SVS) reporting standards criteria for
patency to allow a more accurate comparison of this series
with bypass outcomes.11 The minimum standard of docu-
mented flow by arteriography or DUS was required for a
vessel to be considered patent. Treatment failure was de-
fined as any patient who required reinterventions, whether
for restenoses or occlusions.
Freedom from secondary restenosis was determined by
the last available vascular laboratory study inclusive of pa-
tients who had undergone infrapopliteal reintervention by
endovascular as well as bypass to maintain or restore flow.
The same DUS examination threshold was used for this
determination.
Limb salvage was defined as freedom from major am-
putation (below or above knee). Toe, ray, or transmetatar-
sal amputations were considered minor amputations.
Wound healing or symptom resolution was documented as
complete, improved, stable, or worse.
Reintervention included repeat infrapopliteal PTA or
bypass graft procedure. Repeat PTA was any attempt at a
catheter-based intervention in the tibial lesion(s) previously
intervened on. Reintervention by bypass graft was any
bypass performed in the ipsilateral limb to an infrapopliteal
target encompassing the previously treated area. Survival
was assessed using computerized hospital medical records
and verified by referencing the Social Security Death Index
(http://ssdi.rootsweb.com).
Postoperative complications included any complication
that increased length of stay or required blood transfusion,
operation, or additional therapy. Intraprocedural compli-
cations were those that occurred while in the fluoroscopy
suite or operative room and included flow-limiting spasm
or thromboembolus. No vessel ruptures occurred in this
series.
Statistical analysis. All analyses were performed on a
per-limb basis. Preoperative characteristics and outcomes
were reported as percentages of the sample. Categoric
variables were analyzed by Pearson 2 and the Fisher exact
test. Median length of stay was compared using the Wil-
coxon rank sum test. Treatment outcomes during the
course of follow-up were analyzed using Kaplan-Meier
methodology, and time-to-failure curves were compared by
the log-rank test. Univariate and multivariate Cox regres-
sion models were used to assess predictor variables for
time-dependent outcomes. Primary restenosis, reinterven-
tion, or amputation was assessed both with inclusion and
exclusion of technical failures; however, the final reported
tables are representative of the entire series as an intention
to treat model. Statistical significance was defined as P 
.05. All statistical tests were done using STATA 8 software
(StataCorp, College Station, Tex).RESULTS
Demographics. Tibial PTA was used to treat 176
limbs in 163 patients. Demographics are summarized in
Table II. Median age was 73 years (range, 39-94 years).
Most patients were men with hypertension, diabetes, hy-
perlipidemia, and coronary artery disease. Half of the pa-
tients had a history of smoking. Of the 163 patients, 47
(27%) had undergone a prior infrainguinal bypass in the
limb intervened on, and 40 (23%) were considered unsuit-
able candidates for bypass. The lesions that underwent
intervention were evenly distributed among the TASC
subsets.
Indication for intervention. Most patients were
treated for tissue loss, and a lesser number were treated for
rest pain (15%) or vein graft outflow stenosis (7%; Table II).
More TASC A lesions (8 of 12) were performed for vein
graft outflow stenosis than other TASC classifications.
Procedural details. Stents were placed in infrapopli-
Table II. Demographic data of patients undergoing
infrapopliteal angioplasty
Variables No. or median % or range
Age, years 73 39-94
Male 103 59
Comorbidities
Hypertension 158 90
Diabetes mellitus 126 72
Hyperlipidemia 104 59
Coronary artery disease 106 60
Dialysis-dependant renal failure 29 16
Creatinine 2.0 mg/dL 40 23
Prior myocardial infarction 41 23
Congestive heart failure 55 31
Cerebrovascular disease 36 20
COPD 15 9
Smoker 80 50a
Preintervention medications
Aspirin 118 67
Clopidogrel 55 31
Warfarin 40 23
Statin 88 50
Prior infrapopliteal bypass 47 27
Indication
Tissue loss 137 76
Rest pain 27 15
Threatened graft 12 7
Not bypass candidate 40
No bypass target 17
No bypass conduit 13
Nonambulatory 3
Medical contraindication 4
Wound over potential targets 2
Severe dementia 1
TASC classification
TASC A 41 23
TASC B 38 22
TASC C 46 26
TASC D 51 29
COPD, Chronic obstructive pulmonary disease; TASC, TransAtlantic
InterSociety Consensus.
aMissing values excluded from denominator.teal vessels in 8% of limbs. Four were placed for flow-
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placed for residual stenosis. The stents included six self-
expanding stents, six stainless steel balloon expandable
stents, and three drug-eluting balloon expandable stents.
No significant differences existed among the demographics
of patients receiving stents or for outcomes of restenosis,
reintervention, or amputation after stenting vs angioplasty
only.
Antegrade access was used in 13% of cases. The primary
method of intervention was PTA; however, three arthrec-
tomies were performed. Two patients underwent 24-hour
thrombolysis of an infrapopliteal vessel, followed by PTA
after a stenotic lesion was discovered. A total of 102 pa-
tients (58%) had concomitant femoropopliteal angioplasty
or stenting, or both. No significant differences were found
between groups undergoing single vs multilevel interven-
tions among procedural indications, prior distal bypass
grafts, technical success, or restenosis.
Technical success. Technical success was obtained in
163 of 176 limbs (93%). TASC class predicted technical
success, with the only technical failures occurring in TASC
D lesions (100% for TASC A to C vs 75% for TASC D; P
.0001). Of the 13 technical failures, eight had secondary
interventions, one had immediate amputation, and four
had no further interventions. Of the eight secondary inter-
ventions, five underwent immediate bypass and four had
tibial PTA (1 after bypass failure). Amputation was ulti-
mately required in one of the bypass patients and in two of
the repeat tibial PTA patients. The remaining reinterven-
tions remained patent at last follow-up. Of the four patients
in whom no further procedure was performed, one died at
home 1 month and two continue to receive wound care
for stable wounds. The remaining patient had a concurrent
angioplasty in the superficial femoral and popliteal arteries
and a toe amputation healed. Technical outcome was inde-
pendent of stent placement, multilevel interventions, and
adjunctive procedures.
Intraprocedural complications. Procedural compli-
cations occurred in 10%: flow-limiting spasm (n 9), vessel
perforation (n  1), and thromboembolus (n  8). The
difference in the rate of complications among TASC classes
was not significant (P  .284). In addition, no significant
difference was found in the number of intraprocedural
complications based on the preoperative use of aspirin (P
.602) or clopidogrel (P  .282). All complications were
successfully treated using repeated PTA alone in 4, intra-
arterial vasodilators in 6, or rheolytic thrombectomy in 8,
or thrombolysis in 9, or both. No patient required emer-
gency surgery, and no potential infrapopliteal bypass tar-
gets were compromised.
Perioperative mortality and postoperative compli-
cations. Five patients died for an in-hospital mortality of
3%, and four other patients died after discharge 30 days
from their procedure, for a 30-day mortality of 5%. Two
deaths on postprocedure day 1 included a cardiac arrest and
an uncontrolled retroperitoneal hemorrhage. The remain-
ing in-hospital deaths occurred 3 weeks in patients who
had undergone additional procedures. Twowere secondaryto septic complications, and one patient sustained a myo-
cardial infarction with acute renal failure. The four out-of-
hospital perioperative deaths were from unknown causes.
The postoperative complication rate was 9%. Two
pseudoaneurysms were treated with thrombin injection.
Five hematomas occurred, one retroperitoneal, one rectus,
and three groin (two were surgically evacuated). Conges-
tive heart failure complicated the course of two patients,
and myocardial infarctions occurred in two others. Two
patients had temporary dysrhythmia, and transient contrast
nephropathy developed in four patients.
Length of stay. The median total length of stay was 4
days (range, 0-41 days), whereas the postprocedural length
of stay was 2 days (range, 0-38 days). The median length of
stay was longer for those intervened on for tissue loss
compared with other indications (5 vs 2 days; P  .0005).
Patients with postoperative complications also had median
longer hospitalizations than those without complications
(8 vs 3 days; P .005). Discharge destination was home in
75% and to a rehab facility in 25%.
Follow-up outcomes
Freedom from restenosis, reintervention, or ampu-
tation. Mean follow-up was 10 months (range, 1-41
months). Freedom from restenosis, reintervention, or am-
putation was 39% at 1 year and 36% at 2 years (Fig 1, A).
Freedom from restenosis, reintervention, or amputation at
1 year for TASCA throughDwas 50%, 39%, 53%, and 14%,
respectively (P  .0001; Fig 1, B). TASC D lesions had a
higher restenosis, reintervention, or amputation rate than
all others (Fig 1, C), even when technical failures are
excluded (P  .005). Because all technical failures were
TASC D, this confirms the significant effect of TASC D
regardless of the initial technical success. Freedom from
restenosis, reintervention, or amputation at 1 and 2 years
for bypass graft candidates (46%, 41%) was higher than for
unsuitable bypass candidates (19%, 19%).
TASCD lesions predicted restenosis, reintervention, or
amputation whether technical failures were included or
excluded: including failures had a hazard ratio (HR) of 3.5
(95% CI, 2.2-5.6, P  .001) and excluding failures had a
HR of 2.3 (95% CI, 1.3-4.1, P .005). Univariate predic-
tors of restenosis, reintervention, or amputation were
TASC D classification and patients who were not candi-
dates for bypass (Table III). The strongest predictor within
the bypass candidacy group was a lack of a bypass target
vessel (HR, 2.9; 95% CI, 1.6-5.5, P  .001). Patients
intervened on for graft outflow stenosis had a lower risk.
Age, sex, other comorbidities, procedure indication, and
multilevel disease were not significant factors. On multivar-
iate analysis, TASCD classification and lack of bypass target
remained significant predictors.
A subset analysis excluded all procedures in which
multilevel interventions were performed to ensure that this
was not a significant factor influencing restenosis. In the 74
patients who underwent intervention for isolated infrapop-
liteal lesions, freedom from restenosis, reintervention, or
amputation at 1 and 2 years was 37%, with a significant
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significantly different than that of the entire series (P 
.538). TASC D class and lack of bypass target similarly
predicted restenosis, reintervention, or amputation onmul-
tivariate analysis (TASC D: HR, 2.5 [95% CI, 1.2-5.2, P
Fig 1. A, The primary freedom from restenosis, reintervention,
or amputation at 1 year rises to 42% when technical failures are
excluded. The standard error (SE) remains 10% throughout. B,
Freedom from restenosis, reintervention, or amputation by Trans-
Atlantic InterSociety Consensus (TASC) classification. A carat
indicates where SE 10%. The SE remains 10% throughout for
the TASCD curve.C, Freedom from restenosis, reintervention, or
amputation by TASC D, technical success only. The SE remains
10% throughout for both curves..015]; no target: HR, 3.8 [95% CI, 1.4-10.3; P  .007]).Primary patency. Primary patency was 53% and 51%
at 1 and 2 years (Fig 2, A). Patency at 1 year for TASC A
through D was 53%, 58%, 67%, and 37%, respectively (P
.001). Multivariate predictors of loss of primary patency
were TASC D classification and unsuitable bypass candi-
dacy (Table IV).
Secondary restenosis. Freedom from secondary re-
stenosis was 63% at 1 year and 61% at 2 and 3 years, with a
significant difference among TASC classification as well
(P  .001; Fig 3). Freedom from secondary restenosis for
TASC A through D at 1 year was 79%, 82%, 57%, and 43%,
respectively. On univariate analysis, secondary restenosis
was predicted by TASC D classification, whereas TASC A
and B lesions resulted in lower rates. On multivariate
analysis, TASC D and lack of bypass target predicted sec-
ondary restenosis, but multilevel interventions were protec-
tive (Table V).
Limb salvage and wound healing. Mean follow-up
assessing wound healing was 12 months (range, 1-43
months). At the last follow-up for those with an indication
Table III. Predictors of restenosis, reintervention, or
amputation after infrapopliteal angioplasty
Predictors HR 95% CI P
Univariate
TASC A 0.6 0.3-1.1 .082
TASC B 0.7 0.4-1.3 .233
TASC C 0.6 0.4-1.1 .091
TASC D 3.5 2.2-5.6 0.001a
Female sex 1.5 0.9-2.3 .109
Hypertension 2.5 0.8-7.9 .124
Hyperlipidemia 1.2 0.8-2.0 .398
Diabetes 1.7 0.9-2.9 .095
Coronary artery disease 1.1 0.7-1.7 .748
Dialysis-dependant renal failure 1.1 0.6-2.1 .704
Creatinine 2.0 mg/dL 0.7 0.4-1.3 .294
Cerebrovascular disease 1.0 0.6-1.7 .940
Smoking 1.1 0.6-1.7 .835
Aspirin 0.9 0.6-1.5 .730
Clopidogrel 1.1 0.7-1.9 .594
Warfarin 1.6 0.9-2.6 .086
Statin 1.1 0.7-1.8 .637
Prior distal bypass 0.9 0.5-1.4 .532
Not bypass candidate—all 2.1 1.3-3.5 .002a
No bypass target 2.9 1.6-5.5 .001a
No bypass conduit 1.5 0.7-2.8 .299
Other 1.3 0.4-4.0 .703
Indication
Tissue Loss 1.1 0.6-1.9 .715
Rest pain 1.6 0.9-2.9 .112
Graft outflow stenosis 0.3 0.1-0.97 .043a
Multilevel intervention 0.9 0.5-1.4 .541
Stent placement 0.9 0.3-2.3 .760
Procedural complication 1.0 0.5-2.0 .926
Systemic complication 1.2 0.6-2.5 .651
Multivariate
TASC D 3.4 2.1-5.5 .001a
No bypass target 2.7 1.4-5.0 .003a
CI, Confidence interval; HR, hazard ratio; TASC, TransAtlantic
InterSociety Consensus.
aSignificant value.of tissue loss, wounds were completely healed or improved
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with an indication of rest pain, improvement was noted in
57%, unchanged symptoms in 22%, and worsening in 17%.
Limb salvage at 1, 2, and 3 years was 84% (Fig 4). A
total of 21 amputations were performed 1 year, of which
11 occurred at an interval after a second attempt at revas-
cularization (9 angioplasties, 2 bypasses). Additional at-
tempts at revascularization were not considered to be ap-
propriate. Eleven patients going on to amputation had
failed bypass grafts before PTA in the leg intervened on.
Multivariate predictors of limb loss were TASC D lesions
and bypass candidacy status (Table IV).
Survival. Survival was 80%, 63%, and 54% at 1, 2, and
3 years (Fig 5). Unsuitable bypass candidacy status for
reasons other than lack of target or conduit was predictive
of death (HR, 13.3; 95% CI, 6.4-27.5; P  .001). TASC
class did not predict survival.
Reintervention. At 1 and 2 years, freedom from by-
pass was 85%, freedom from repeat infrapopliteal PTA was
74% and 72%, and freedom from either PTA or bypass was
63% and 61% (Fig 6). Three patients had subsequent SFA
angioplasties but were noted to have patent tibial vessels
Fig 2. Primary patency rates as determined by conventional cri-
teria. The standard error (SE) remains 10% throughout.
Table IV. Predictors of primary patency, amputation,
and reinterventiona after infrapopliteal angioplasty
Multivariate HR 95% CI P
Primary patency
TASC D 2.8 1.6-4.7 .001b
Not bypass candidate—all 2.2 1.3-3.9 .004b
Amputation
Not bypass candidate—all 6.3 2.5-15.4 .001b
TASC D 2.6 1.1-6.3 .033
Reintervention PTA
Not bypass candidate—all 4.6 2.2-9.4 .001b
CI, Confidence interval; HR, hazard ratio; TASC, TransAtlantic
InterSociety Consensus.
aThere were no significant predictors of reintervention by bypass graft.
bSignificant.at that procedure. On multivariate analysis, noncandi-dacy for bypass was predictive of reintervention by tibial
PTA (Table IV). TASC classification was not predictive
Fig 3. A, Freedom from secondary restenosis. The standard error
(SE) remains 10% throughout. B, Freedom from secondary
restenosis by TransAtlantic InterSociety Consensus (TASC) clas-
sification. The carat indicates when the SE10% for TASCC. The
SE remains 10% throughout for all other TASC subgroups.
Table V. Predictors of secondary restenosis after
infrapopliteal angioplastya
Predictors HR 95% CI P
Univariate
TASC A 0.4 0.2-0.9 .027b
TASC B 0.3 0.1-0.97 .044b
TASC C 1.2 0.7-2.3 .490
TASC D 3.4 1.7-6.7 .001b
Not bypass candidate—all 2.9 1.6-5.2 .001b
No bypass target 5.8 2.9-11.7 .001b
No bypass conduit 0.8 0.3-2.3 .734
Other 2.5 0.8-8.2 .124
Multilevel intervention 0.4 0.2-0.8 .006b
Multivariate
No bypass target 6.1 2.9-12.7 .001b
TASC D 2.8 1.5-5.0 .001b
Multilevel intervention 0.4 0.2-0.8 .006b
CI, Confidence interval; HR, hazard ratio; TASC, TransAtlantic
InterSociety Consensus.
aComorbidities, indication, stent placement, intraprocedural complications,
and systemic complications were non-significant on univariate analysis.
bSignificant.of reintervention.
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This study demonstrates that initial technical success
as well as restenosis and limb salvage depends on TASC
classification. TASC D lesions fared significantly worse
Fig 4. Limb salvage (freedom from amputation). All amputations
occurred before 1 year. The standard error remains 10%
throughout.
Fig 5. Overall survival. The standard error remains 10%
throughout.
Fig 6. Freedom from reintervention by bypass graft (BPG), re-
peat infrapopliteal percutaneous transluminal angioplasty (PTA),
or either. The standard error remains 10% throughout.compared with other classifications. Noncandidacy forbypass was also independently predictive of restenosis
and amputation, which highlights that the outcomes
after distal bypass may not be directly comparable with
endovascular interventions. These findings provide
strong evidence that TASC class coupled with surgical
candidacy is an objective tool that can help to guide
clinical decisions.
The decision to report outcomes in the current series as
freedom from restenosis, reintervention, or amputation, as
well as the traditionally defined primary patency, was made
to allow for comparisons not only with endovascular liter-
ature but also with bypass series. Results reported within
endovascular series vary significantly; however, the term
“primary patency” in reference to percutaneous interven-
tions is often used to refer to freedom from restenosis rather
than freedom from occlusion or reintervention, as is more
commonly reported in bypass literature.
In addition to the variability in follow-up measure-
ments, endovascular reports also lack uniformity in regard
to procedural indication, segmental and multilevel disease,
and lesion characteristics, making broad conclusions diffi-
cult.10,12-25 A recent analysis by Kudo et al10 of aortoiliac,
femoropopliteal, and infrapopliteal interventions for CLI
and also found TASC D lesions to have an adverse impact
on restenosis.10 Their series included 52 infrapopliteal
PTAs with a 3-year freedom from restenosis of 24% 11%.
The effect of TASC class was not analyzed specifically
within the infrapopliteal subset, however. Haider et al12
reported a 1-year freedom from occlusion or reintervention
of 67% in 32 limbs undergoing infrapopliteal PTA. They
modified the TASC score to reflect the worst TASC lesion
of the treated limb, but not necessarily the TASC of the
treated vessel. All lesions except one in the infrapopliteal
cohort were classified as TASC D. Limb salvage at 1 year
was 82%, but restenosis was not reported as an outcome.
Earlier reports have even greater variability in outcomes
with less objective measurement criteria to assess restenosis
or occlusion. In 1996 Lofberg et al13 reported 86 infrap-
opliteal interventions for CLI, defining clinical success as
symptomatic improvement and an increase in ABI of0.1.
Rates for 1-, 2-, and 3-year clinical success were 51%, 36%,
and 36%, respectively, and 3-year limb salvage was 72%.13
Dorros et al14 reported a large series of 215 patients who
had undergone tibial PTA for rest pain or tissue loss and
found that bypass surgery occurred in 8% and amputation
in 9%. Proximal interventions were performed in 59%.
Lesions were described as stenotic (71%) or occlusive (29%)
but were not characterized further. Unfortunately, no out-
comes were reported for restenosis, occlusion, or repeat
PTA.14
Faglia et al15 reported a series of 221 angioplasties for
ischemic diabetic foot ulcers, of which 42% were performed
only in infrapopliteal arteries, 6% in femoropopliteal arter-
ies, and 52% in both levels. A clinical recurrence (pain or
worsening ulcer) occurred in 7.3%, and 5% had repeat PTA.
Average time to recurrence was 4.6 months, and 5% under-
went major amputation. Follow-up ABI and DUS evalua-
tion were only performed in cases of clinical recurrence.15
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outcomes of infrapopliteal PTA done in 1282 limbs. Pro-
cedural indication was CLI in 86% and claudication in 14%.
Primary patency was 79% at 1 year and 74% at 2 years;
however, patency definitions were not delineated. Limb
salvage at 2 years was 74%.16
Although our current series has a low freedom from
restenosis, reintervention, or amputation of 39%, primary
patency is 53%, and freedom from secondary restenosis is
63%. This approaches bypass outcomes even though nearly
one-quarter of the patients were unsuitable candidates for
bypass. The Edifoligide for the Prevention of Infrainguinal
Vein Graft Failure (PREVENT III) trial of bypass grafts
performed for critical limb ischemia reported a trial out-
come analogous to our measure of restenosis, reinterven-
tion, or amputation, defined by PREVENT III as freedom
from clinically significant graft stenosis, reintervention, or
amputation. The two study arms had a 1-year outcome of
44% and 46% compared with 39% in our series. The 1-year
primary patency in that trial was 61%, highlighting the
discrepancy of patency measurement methods reported in
bypass vs endovascular series. Moreover, the 1-year limb
salvage rate of 84% in our series compares favorably with the
88% rate in PREVENT III.26 These similarities with bypass
outcomes show that with diligent follow-up and aggressive
reintervention, including bypass in 15% of patients at 2
years, limb salvage can be maintained.
A relatively high postoperative complication and 30-
day mortality rate coupled with the 1- and 3-year survival
rates seen in this study of 80% and 54% are an indicator of
the overall burden of illness that these patients carry.27
Patients who preferentially undergo a percutaneous inter-
vention tend to be sicker than patients in whom bypasses
are the first line of treatment. The long length of stay and
need for additional postdischarge services for a procedure
that could be performed with an overnight stay indicate
other factors necessitating hospital care are often present.
An attempt at percutaneous intervention may be per-
formed as a “salvage” procedure in patients who have
limited life expectancies and extensive comorbidities who
would have otherwise undergone a primary amputation,
which is associated with perioperative mortality rates of 5%
to 17%.28,29 In our study, only two deaths occurred with a
close temporal relationship to the percutaneous procedure;
nonetheless, the 30-day mortality of 5% was still higher
than the 1.7% to 2.4% seen in other infrapopliteal angio-
plasty series.13,30 It is difficult, however, to attribute these
perioperative deaths directly to the intervention rather than
overall illness severity. The pedal bypass series at our insti-
tution reported a 30-day mortality of 0.9%.1 The same
series had a 2-year mortality rate of 25% vs the 37% seen
here. Other distal bypass series have reported 30-day mor-
tality rates of 2.1% to 5%.5,7
This study also reports an overall intraprocedural
complication rate of 10%, which is not low. After noting
high thrombotic and spasm rates in the early phases of
this series, we increased the goal procedural ACT to
300 and began routine use of intra-arterial vasodilatorsbefore PTA. We also take care to visualize the wire tip
during catheter exchanges to prevent distal migration.
Although thrombotic complications may be related to
lack of preoperative dual antiplatelet therapy rather than
systemic anticoagulation, we noted only one thrombo-
embolic complication in the second half of our series. In
addition, arterial spasm would not be affected by anti-
platelet therapy.
The choice between PTA and surgery is made at the
time of arteriography, without a separate diagnostic arte-
riogram. We prefer not to operate on patients who are
taking clopidogrel, and because most of our cases involve
tissue loss, we prefer not to delay surgery; therefore, we do
not initiate clopidogrel before arteriography. Technical
failure, intraprocedural complications, and restenosis were
found to be unrelated to daily preoperative aspirin or
clopidogrel use on analysis. All intraprocedural complica-
tions were managed in an endovascular fashion. No patient
required emergency surgery to correct a procedural com-
plication.
Although the minimally invasive nature of infrapopli-
teal PTA has obvious appeal, it also has potential disadvan-
tages. These may include conversion of an elective to
emergency procedure, loss of bypass targets, a less durable
solution, lengthy procedures causing excessive radiation
exposure, and the potential for rising costs of care if multi-
ple interventions are necessary. The delay to surgery caused
by an inadequate or failed intervention could cause in-
creased ischemia and lead to worsening wounds, minor
amputations, and even limb loss, despite the ability to
construct a durable bypass graft.
This study has several limitations. It is a retrospective
analysis and thus is vulnerable to the bias inherent in that
study design. The patient cohort was not homogenous,
because many were not considered candidates for bypass.
Candidacy for bypass is often subjective and based on a
variety of clinical factors. Redo bypasses requiring multiple
segments of vein in patients with poor cardiac function and
limited mobility may be technically possible but are not an
appealing option. Initially, we chose to seek a percutaneous
intervention only in patients who were not optimal candi-
dates for bypass. With experience we began treating a
broader range of patients.
CONCLUSIONS
This study demonstrates that technical success, free-
dom from restenosis, reintervention, or amputation, pa-
tency, secondary restenosis, and limb salvage with infrap-
opliteal PTA can be predicted by TASC class and surgical
bypass candidacy. Although high rates of restenosis occur,
with careful follow-up and reintervention with either repeat
PTA or bypass, secondary restenosis and limb salvage com-
parable with bypass can be achieved. This proceduremay be
an appropriate alternative for the patient who is not an
optimal candidate for bypass and may also be a reasonable
first-line treatment for TASC A, B, and C lesions in those
patients who are good bypass candidates. Additional long-
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